Anavex Life Sciences Corp (AVXL)

[crescentmotor]

it's quite noticeable that the dosed and placebo lines only begin to seriously diverge during the last 12 week period

That's where many of us went wrong. At the 48 week mark, the lines have only begun to separate and Blarcamesine didn't exactly have the look of a miracle drug treatment for AD. But as time went on to the 144 week mark, the OLE data began to look stronger than dirt. Unfortunately, some of us assumed that such impressive OLE data would play a prominent role in the CHMP decision-making process. It didn't happen.